Premium
System issues: Mutagenic response to benzene and Tris (2,3‐dibromopropyl)‐phosphate in the lambda lacl transgenic mouse mutation assay: A standardized approach to in vivo mutation analysis
Author(s) -
Provost G. S.,
Mirsalis J. C.,
Rogers B. J.,
Short J. M.
Publication year - 1996
Publication title -
environmental and molecular mutagenesis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 87
eISSN - 1098-2280
pISSN - 0893-6692
DOI - 10.1002/(sici)1098-2280(1996)28:4<342::aid-em7>3.0.co;2-d
Subject(s) - spleen , mutagenesis , carcinogen , mutation , genetically modified mouse , microbiology and biotechnology , biology , genotoxicity , in vivo , bone marrow , kidney , mutagen , ratón , transgene , toxicity , biochemistry , immunology , genetics , medicine , gene
Abstract The genotoxic response of benzene and tris (2,3‐dibromopropyl)‐phosphate (TDBP) have been evaluated in several tissues using the standardized lambda/ lacl (Big Blue®) transgenic mouse mutation assay. Separate groups of four to five male B6C3F 1 transgenic lambda/ lacl mice were given oral administrations of benzene or TDBP at varying concentrations. Tissues evaluated include lung, bone marrow, and spleen in benzene‐treated animals, and liver, kidney, and stomach in TDBP‐treated animals. Significant increases in lacl mutations were observed in the spleen and bone marrow of benzene treated mice, and the kidneys of TDBP‐treated mice. Where applicable, mutagenesis patterns of tissue sensitivity were consistent with what has been observed previously in other assays. In addition, mutagenicity in tissues not traditionally evaluated for mutations correlated to sites of carcinogenicity for the chemicals tested. © 1996 Wiley‐Liss, Inc.